[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:pten-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"PTEN Gene",24,20,[8,16,23,30,36,42,48,54,60,66,72,78,84,90,96,102,108,114,120,126,132,139,145,152],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06638307","A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.765634Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05455619","Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+\u002FHer2- Breast Cancer",[20],"Phase 1\u002FPhase 2","2026-08-26T02:16:28.221034Z","2026-05-05T02:47:14.270026Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06738303","Cabazitaxel +\u002F- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer",[27],"Phase 2","2026-08-26T02:15:59.318403Z","2026-05-05T02:43:29.025195Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06085729","Phase I\u002FII Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)",[20],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:27.927821Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05593497","A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss",[27],"2026-08-26T02:17:17.791881Z","2026-05-05T02:43:27.827255Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT02523014","Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas",[27],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:27.482521Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05843253","Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant",[27],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:29.388169Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05691465","Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells",[27],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:28.481085Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05039801","IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors",[12],"2026-08-26T02:18:49.989941Z","2026-04-29T02:57:57.070174Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT07426822","Rash & Diarrhea Prophylaxis With Capivasertib",[27],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.658046Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05941520","Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer",[27],"2026-08-26T02:17:39.048487Z","2026-07-19T19:36:05.126907Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06195306","Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",[27],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:26.724920Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT05933395","Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4\u002F6 Inhibitor",[27],"2026-08-26T02:15:24.145250Z","2026-05-05T02:43:29.132138Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT03729115","A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer",[],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:26.901351Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT07218666","Zanzalintinib in Men With Aggressive Variant Prostate Cancer",[27],"2026-08-26T02:16:26.411851Z","2026-07-19T19:36:05.140412Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07038785","Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs",[],"2026-08-26T02:18:38.865010Z","2026-05-13T02:55:06.608906Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06888388","Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer",[],"2026-08-26T02:17:58.890423Z","2026-05-13T02:55:06.588403Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT02302742","Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry",[],"2026-08-26T02:17:28.381459Z","2026-05-13T02:55:06.091980Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT02461446","Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations",[],"2026-08-03T03:16:58.558447Z","2026-05-13T02:55:06.095409Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT01034033","Genetic & Pathological Studies of BRCA1\u002FBRCA2: Associated Tumors & Blood Samples",[],"2026-08-26T02:19:30.857183Z","2026-05-13T02:55:06.066896Z",{"nct_id":133,"title":134,"phases":135,"status":137,"updated_at":14,"content_modified":138},"NCT07218575","Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations",[136],"Phase 2\u002FPhase 3","NOT_YET_RECRUITING","2026-06-05T00:55:50.372501Z",{"nct_id":140,"title":141,"phases":142,"status":137,"updated_at":143,"content_modified":144},"NCT07690852","Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care",[],"2026-08-26T02:16:24.970704Z","2026-07-19T19:36:05.153122Z",{"nct_id":146,"title":147,"phases":148,"status":149,"updated_at":150,"content_modified":151},"NCT05563220","Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:12:21.768801Z","2026-05-05T02:43:29.025043Z",{"nct_id":153,"title":154,"phases":155,"status":149,"updated_at":156,"content_modified":157},"NCT06029998","Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion",[27],"2026-08-03T02:05:27.322885Z","2026-05-05T02:43:27.110268Z"]